August 13, 2020
In this month’s researcher update, please find information on:
To support ongoing epilepsy research projects during the pandemic, CURE has launched the Epilepsy Research Continuity Fund. This grant will provide reimbursements of up to $15,000 for research related expenses resulting from institutional shutdowns due to COVID-19 and for which institutional support was not available or provided.
We are now accepting applications and will close the submission period on Monday, August 31, 2020 at 9:00PM ET. This award is available to early career investigators. You can find the full Request for Applications on the CURE website. Special consideration will be given to current and previous CURE grantees.
The Centers for Disease Control and Prevention (CDC) Epilepsy Program announced a new, non-research funding opportunity designed to improve health and quality of life for people with epilepsy. This funding is intended to implement strategies that target social factors to reduce stigma and improve health, social participation, and quality of life for people with epilepsy.
The National Heart, Lung and Blood Institute and the National Institute of Neurological Disorders and Stroke are soliciting grant applications focused on evaluating causes and consequences of and risk factors for sudden death in the young (SDY). Proposals are required to use data and DNA samples, as well as associated sequence data from the NIH/CDC SDY Case Registry as a basis of the research.
The RELA is a comprehensive survey of 44 rare epilepsy organizations, which explores their founding and mission, while shedding light on shared challenges. Since the initial analysis, this project has brought together over 100 organizations to collaborate around research, information, support, professional education, and advocacy opportunities. As an outgrowth of the Rare Epilepsy Network (REN), this survey was made possible by a contract from the Epilepsy Foundation and developed in consultation with rare organization leaders and epilepsy stakeholders, including CURE.